Nkarta, Inc. (NKTX)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Nkarta Highlights Clinical Trial Advances in Annual Update
# 📄 Document Overview This is Nkarta, Inc.'s (NKTX) **Annual Report to Shareholders (ARS)**. Think of it as the company's annual "report card" sent directly to its owners (the shareholders). It combines the formal 10-K filing with a more graphical, summarized, and often more visually engaging pres
Nkarta Shareholders to Vote on Director Elections and Compensation
# 🔍 **Nkarta, Inc. (NKTX) Proxy Statement Breakdown** This document is a **Definitive Proxy Statement (DEF 14A)** for Nkarta's 2026 Annual Meeting of Stockholders. It outlines proposals for stockholders to vote on and provides essential company governance, director nominations, and executive compe
SEC filings
All filings →Insider trades
All insider trades →Nkarta, Inc. has no reported insider trades in the last 90 days.